Patent ID: 8088826

Claim:
A process for controlling a urological disorder or disease selected from urinary incontinence, overactive bladder, and urge urinary incontinence in a human or animal comprising administering to the human or animal a VR1-antagonisticly effective amount of at least one compound represented by the formula: wherein R 1 represents hydrogen or C 1-6 alkyl; X represents —N(H)Y 1 , —N(H)—C 1-6 alkyleneY 1 , biphenyl or C 1-6 alkyl substituted by biphenyl; wherein said biphenyl is substituted by Z 1 , Z 2 , and Z 3 ; Y 1 represents biphenyl substituted by Z 3 , Z 4 and Z 5 ; Z 1 and Z 2 are identical or different and represents hydrogen, halogen, carboxy, nitro, C 1-6 alkyl optionally substituted by cyano or mono-, di-, or tri-halogen, C 1-6 alkoxy optionally substituted by morpholino, or mono-, di, or tri-halogen, C 1-6 alkylthio, amino, C 1-6 alkyamino, di(C 1-6 alkyl)amino, C 1-6 alkylsulfinyl, C 1-6 alkanoyl, or C 1-6 alkoxycarbonyl; Z 3 represents hydrogen, halogen, amino, pyrrolidinyl, piperidino, piperazinyl, homopiperidino, C 1-6 alkoxy optionally substituted by mono-, di-, or tri-halogen, or C 1-6 alkyl optionally substituted by mono-, di-, or tri-halogen; Z 4 represents halogen, carboxy, nitro, C 1-6 alkyl optionally substituted by cyano or mono-, di-, or tri-halogen, C 1-6 alkoxy optionally substituted by morpholino, or mono-, di-, or tri-halogen, C 1-6 alkylthio, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 1-6 alkylsulfinyl, C 1-6 alkanoyl, or C 1-6 alkoxycarbonyl; and Z 5 represents hydrogen, halogen, carboxy, nitro, C 1-6 alkyl optionally substituted by cyano or mono-, di-, or tri-halogen, C 1-6 alkoxy optionally substituted by morpholino, or mono-, di-, or tri-halogen, C 1-6 alkylthio, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 1-6 alkylsulfinyl, C 1-6 alkanoyl, or C 1-6 alkoxycarbonyl; or Z 4 and Z 5 together with the carbon atom to which they are attached, form a benzene ring.